Who We Serve

Our systems are trusted worldwide, uncovering new data layers that advance the future of personalized medicines.


  • IsoPlexis' Blood-Based Biomarker Predicts Response and Progression-Free Survival to a Novel IL-2 Agonist and Checkpoint Inhibitor Doublet Therapy in a Phase 2 Study of Metastatic Melanoma Patients
  • IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing
  • Clinical Data Highlighting Single-Cell Polyfunctionality as a Potential Predictor of Patient Response to CAR-T Cell Therapy Published in "Blood"


  • IsoPlexis' Expanded Cell Therapy Offerings Demonstrated in Nature Medicine Publications
  • IsoPlexis and Yale Partner to Advance COVID-19 Immune Profiling Biomarkers
  • IsoPlexis Adds Partnership to Advance COVID-19 Vaccine Development
  • IsoPlexis and Institute for Systems Biology partner to uncover the functional immune mechanisms behind COVID-19 response

Recent Publications

Our Customers

Enabling a new era of precision medicine

Spark the Next Breakthrough